HSR&D Citation Abstract
Search | Search by Center | Search by Source | Keywords in Title
Sarcopenia in Immune-Mediated Rheumatic Diseases-Review.
Santo RCDE, Baker JF, Santos LPD, Silva MMMD, Xavier RM. Sarcopenia in Immune-Mediated Rheumatic Diseases-Review. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2023 Oct 1; 29(7):354-362.
Sarcopenia is a condition characterized by decreased muscle strength and muscle mass, which can impact physical function. Sarcopenia develops as a consequence of age-related decline (primary sarcopenia) and has a major impact on physical, social, and emotional well-being. In addition, patients with rheumatic diseases may suffer from sarcopenia independently of aging (secondary sarcopenia). Exercise, pharmacological treatments, and nutritional supplementation are some of the strategies used for the management of sarcopenia in the general population. The aim of this review is to summarize the evidence around the prevalence and impact of sarcopenia in patients with rheumatic diseases.
From our review, we can state that sarcopenia is a common and prevalent condition among the rheumatic diseases. Furthermore, the impacts of sarcopenia are not well-appreciated, and the implementation of treatment strategies has not been widespread. Strategies such as exercise and some pharmacological treatments are effective in improving physical and functional impairment related to these conditions.
FUTURE RESEARCH DIRECTIONS IN THE FIELD:
New pharmacological treatments are being actively studied and may contribute in the future to the management of sarcopenia.